Drug Trial Radar · NCT03708900
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 28, 2021
Primary completion
Jul 21, 2027
Study completion Jul 21, 2027
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
Conditions
- Cushing Syndrome
Interventions
LCI699Drug
osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's SyndromeTime frame: up to Week 12
Locations
15 sites in 7 countries. Site status is shown where the registry gives one.
University of California San Francisco UCSF
San Francisco, California · Recruiting
ABMED Clinical Research Corp
Cape Coral, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois · Recruiting
National Institute of Child Health and Human Development
Bethesda, Maryland · Completed
Texas Valley Clinical Research
Weslaco, Texas · Recruiting
UZ Brussel
Jette, Brussels Capital, Belgium · Completed
Multiprofile Hospital for Active Treatment Sveta Marina EAD
Varna, Bulgaria · Withdrawn
Hospital Necker Enfants Malades
Paris, France · Completed
Robert Debre Hospital
Paris, France · Completed
CHU Bicetre APHP Paris Saclay
Paris, France · Completed
Ospedale Bambino Gesu
Roma, Italy · Completed
Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello
Pisa, PI, Italy · Completed
University Clinical Center Ljubljana
Ljubljana, Slovenia · Withdrawn
Alder Hey Childrens NHS Foundation Trust
Liverpool, United Kingdom · Withdrawn
The Royal London Childrens Hospital
London, United Kingdom · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.